Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Innovation Fund Denmark","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"Scandion Oncology receives DKK 5 million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical development plans for SCO-101","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"DENMARK","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCO-101 works in synergy with the chemotherapy drug docetaxel in drug resistant cancer cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Alligator Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alligator Bioscience and Scandion Oncology Sign Preclinical Agreement to Explore Combination Therapies for Chemotherapy and Immuno-oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scandion Oncology Drug SCO-101 Potentiates the Effect of Chemotherapy in the First Cohort in Chemo-Resistant Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scandion Oncology Announces Results from the Next Evaluable Chemo-Resistant Colorectal Cancer Patient Treated with SCO-101 and Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scandion Oncology Receives Final Approval from the Danish Medicines Agency and Ethical Committee for Start of a Clinical Trial in Patients with Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Scandion Oncology

    Menu

    Scandion Oncology

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Scandion Oncology

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Scandion Oncology Receives Final Approval from the Danish Medicines Agency and Ethical Committee for Start of a Clinical Trial in Patients with Pancreatic Cancer

              Details:

              The company has received final approval from the Danish Medicines Agency and Ethical Committee to initiate a clinical trial with the drug candidate SCO-101 in combination with first line chemotherapy in patients with inoperable or metastatic pancreatic cancer.

              Lead Product(s): SCO-101,Taxane

              Therapeutic Area: Oncology Product Name: SCO-101

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 28, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Scandion Oncology

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Scandion Oncology Announces Results from the Next Evaluable Chemo-Resistant Colorectal Cancer Patient Treated with SCO-101 and Chemotherapy

              Details:

              First part of the trial aimed at establishing the safety, tolerability and Maximum Tolerated Dose of SCO-101 in combination with FOLFIRI. One patient has obtained stable disease, according to RECIST version 1.1 at 8 weeks after starting the treatment.

              Lead Product(s): Endovion,Fluorouracil,Calcium Folinate

              Therapeutic Area: Oncology Product Name: SCO-101

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 20, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Scandion Oncology

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Scandion Oncology Drug SCO-101 Potentiates the Effect of Chemotherapy in the First Cohort in Chemo-Resistant Metastatic Colorectal Cancer

              Details:

              The main result of oral SCO-101 potentiates the effects of FOLFIRI. Based on safety data from this first cohort of patients, Data Safety Monitoring Board has recommended to include 3 additional patients at 150 mg SCO-101and FOLFIRI.

              Lead Product(s): Endovion,Fluorouracil,Calcium Folinate

              Therapeutic Area: Oncology Product Name: SCO-101

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 31, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Scandion Oncology

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Alligator Bioscience and Scandion Oncology Sign Preclinical Agreement to Explore Combination Therapies for Chemotherapy and Immuno-oncology

              Details:

              The two companies will explore the anti-tumor effect of the CD40 antibody mitazalimab (Alligator Bioscience) in combination with SCO-101 (Scandion Oncology) as an add-on to chemotherapy in preclinical tumor models that have been shown to be resistant to chemotherapy.

              Lead Product(s): Mitazalimab,SCO-101

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Recipient: Alligator Bioscience

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration June 04, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Scandion Oncology

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SCO-101 works in synergy with the chemotherapy drug docetaxel in drug resistant cancer cells

              Details:

              Based on modelling of preclinical data with docetaxel resistant cancer cells, Scandion Oncology has published that SCO-101 significantly increases the potency of docetaxel.

              Lead Product(s): SCO-101

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 25, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Scandion Oncology

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Clinical development plans for SCO-101

              Details:

              Phase II trial of SCO-101 treats a critical condition with no satisfactory treatment choice, thus Scandion has agreed to continue the research of colorectal cancer with patients resistant to FOLFIRI.

              Lead Product(s): SCO-101

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase I/ Phase II Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 23, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Scandion Oncology

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Scandion Oncology receives DKK 5 million

              Details:

              The grant of DKK 5 million from Innovation Fund Denmark is earmarked for the clinical phase II development of SCO-101 in metastatic pancreatic cancer.

              Lead Product(s): SCO-101,Taxane

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Innovation Fund Denmark

              Deal Size: $0.7 million Upfront Cash: Undisclosed

              Deal Type: Funding February 19, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY